Cover Image
市場調查報告書

EpiCast Report:心房纖維顫動的流行病學的預測

EpiCast Report: Atrial Fibrillation - Epidemiology Forecast to 2025

出版商 GlobalData 商品編碼 300493
出版日期 內容資訊 英文 42 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:心房纖維顫動的流行病學的預測 EpiCast Report: Atrial Fibrillation - Epidemiology Forecast to 2025
出版日期: 2016年08月01日 內容資訊: 英文 42 Pages
簡介

心房纖維顫動(AF)為心臟的電系統的障礙之一,是全球各國老年人的一般心臟疾病之一。全球主要8個國家的心房纖維顫動的確診病患人數,從2013年的10,112,797人,預計2023年增加到12,316,458人。比實際的患病增加人數,各國的人口結構變化對盛行率的變動有更強影響。

本報告提供全球主要8個國家(美國、法國、德國、義大利、西班牙、英國、日本、加拿大)的心房纖維顫動的發病情形和今後預測相關分析、疾病的特徵(風險要素和主要的共生病症等)全球各國的趨勢、目前患病者的發病情形、今後10年的發病、患病數量的預測值等調查評估,將其結果為您概述為以下內容。

第1章 目錄

第2章 簡介

  • 概要
  • 相關調查
  • 近日出版的相關調查

第3章 流行病學

  • 疾病的背景
  • 風險要素和共生病症
  • 全世界的趨勢
  • 預測手法
    • 利用之資訊來源
    • 預測的前提條件與手法
    • 未利用之資訊來源
  • 心房纖維顫動的流行病學預測(今後11年份)
    • 確診的患病人數
    • 確診的患病人數(各年齡)
    • 確診的患病人數(性別)
    • 確診的患病人數(已調整年齡)
    • 確診的患病人數(症狀的各類型)
  • 議論
    • 流行病學性的預測相關結論
    • 分析的限制
    • 分析的優勢

第4章 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHCER123-16

Atrial fibrillation (AF) is a disorder of the heart's conduction system. The condition is characterized by an irregular heart rhythm that is either too fast or too slow. During AF, the two upper chambers of the heart (atria) beat out of coordination with the two lower chambers (ventricles) due to disorganized electrical signals. Consequently, the blood doesn't flow as well as it should from the atria to the ventricles, resulting in poor blood supply to the rest of the body. AF symptoms typically include heart palpitations, chest discomfort, shortness of breath, dizziness, and weakness (CDC, 2015; Mayo Clinic, 2016; NHLBI, 2014). However, individuals with AF may be asymptomatic and not even know that they have the condition until it is identified through an electrocardiogram (ECG) test.

In the 8MM, GlobalData epidemiologists forecast that the diagnosed prevalent cases of AF will increase from 9,487,217 cases in 2015 to 11,536,773 cases in 2025, at an Annual Growth Rate (AGR) of 2.16%. The US will have the highest number of diagnosed prevalent cases of AF among the 8MM throughout the forecast period, while Canada will have the lowest. In the 8MM, permanent AF is forecast to be the predominant subtype of AF. In the US, Germany, Spain, the UK, Japan, and Canada, paroxysmal AF is forecast to be the second most predominant subtype, while persistent AF is the second most common subtype in France and Italy.

Scope

  • The Atrial fibrillation (AF) EpiCast Report is an overview of the risk factors, comorbidities, and the global and historical trends for AF in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Canada). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of AF based on country-specific studies published in peer-reviewed journals. The diagnosed prevalent cases of AF are segmented by age (at 5-year intervals, starting at age 40 years), sex, and clinical subtypes (paroxysmal, persistent, and permanent AF) in the 8MM.
  • The AF epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

The AF EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global AF market.
  • Quantify patient populations in the global AF market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for AF therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Epidemiology

  • 2.1. Risk Factors and Comorbidities
  • 2.2. Global Trends
  • 2.3. Forecast Methodology
    • 2.3.1. Sources Used
    • 2.3.2. Forecast Assumptions and Methods
    • 2.3.3. Sources Not Used
  • 2.4. Epidemiological Forecast for AF (2015-2025)
    • 2.4.1. Diagnosed Prevalent Cases
  • 2.5. Discussion
    • 2.5.1. Epidemiological Forecast Insight
    • 2.5.2. Limitations of the Analysis
    • 2.5.3. Strengths of the Analysis

3. Appendix

  • 3.1. Bibliography
  • 3.2. About the Authors
    • 3.2.1. Epidemiologist
    • 3.2.2. Reviewers
    • 3.2.3. Global Director of Therapy Analysis and Epidemiology
    • 3.2.4. Global Head of Healthcare
  • 3.3. About GlobalData
  • 3.4. About EpiCast
  • 3.5. Disclaimer

List of Tables

  • Table 1: Clinical Subtypes of AF
  • Table 2: Risk Factors and Comorbidities for AF
  • Table 3: Prevalence (%) of AF as Reported in Epidemiological Studies
  • Table 4: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of AF
  • Table 5: 8MM, Sources Used to Forecast Clinical Subtypes of Diagnosed Prevalent Cases of AF
  • Table 6: 8MM, Sources Not Used in the Epidemiological Analysis of AF
  • Table 7: 8MM, Diagnosed Prevalent Cases of AF, Ages ≥40 Years, Both Sexes, N, Selected Years 2015-2025
  • Table 8: 8MM, Age-Specific Diagnosed Prevalent Cases of AF, Both Sexes, N (Row %), 2015
  • Table 9: 8MM, Sex-Specific Diagnosed Prevalent Cases of AF, Ages ≥40 Years, N (Row %), 2015

List of Figures

  • Figure 1: 8MM, Diagnosed Prevalent Cases of AF, Ages ≥40 Years, Both Sexes, N, 2015-2025
  • Figure 2: 8MM, Age-Specific Diagnosed Prevalent Cases of AF, Both Sexes, N, 2015
  • Figure 3: 8MM, Sex-Specific Diagnosed Prevalent Cases of AF, Ages ≥40 Years, 2015
  • Figure 4: 8MM, Age-Standardized Diagnosed Prevalence of AF, Ages ≥40 Years, N, 2015
  • Figure 5: 8MM, Diagnosed Prevalent Cases of AF by Clinical Subtypes, Both Sexes, Ages ≥40 Years, 2015
Back to Top